



CHILDREN'S
Leukaemia & Cancer Research
Foundation (Inc.)
Annual Report 2014



List of Office Bearers	2
Chairman's Report	3-4
Executive Officer's Report	5-7
Children's Leukaemia & Cancer Research Laboratory Report	8 - 12
Financial Statements	
♥ Statement by the Committee of Management	14
♥ Operating Statement as at 30/06/14	15
♥ Balance Sheet as at 30/06/14	16
♥ Audit Report for Year Ended 30/06/14	17
Donations \$100 & Above July 2013 - June 2014	19 - 20
Schedule of Members	21 -24

Children's Leukaemia & Cancer Research Foundation (Inc)

Mr Geoffrey CATTACH, AM
(Chairman)

Mr Philip BRUCE
(Vice Chairman)

Mr Kim WILLIAMSON
(Treasurer)

Mr David CATTACH (Secretary)

Mr Kimon ANDERSON

Mr Justin BRUCE

Professor Cathy COLE
(Nominee of Princess Margaret Hospital)

Ms Natalie HIDDLESTONE

Professor Ursula KEES
(Nominee of Telethon Kids Institute)

Mr Michael PARKER

Mrs Valerie STOPP

Mr John VIEIRA

Founder

Mr Peter HARPER

Trustees

Mr Geoffrey CATTACH

Professor Ursula KEES

Mr Kim WILLIAMSON

Administration Staff

Mrs Andrea ALEXANDER
(Executive Officer)

Mrs Wendy KEARNS
(Executive Assistant)

Miss Katelyn LUSH
(Administrative Assistant)



It is with pleasure that I once again report to members on the operations of the Children's Leukaemia & Cancer Research Foundation (Inc) for the year ended 30th June 2014. In many ways it has been a remarkable year which has seen a consolidation of initiatives previously undertaken, growth in revenue streams, increased research funding and a continued transition from the 'old' to the 'new' in both governance and compliance.

Finance:

Due to a number of significant bequests, the Foundation was able to achieve an outstanding profit of \$1,023,960 for the year under review. This followed on from a profit outcome of \$935,643 for the 2012/13 financial year.

This remarkable outcome far exceeded our budgeted expectations of \$225,000 for 2013/14 and continues to put the Foundation in a strong financial position. The Treasurer will report in greater detail in relation to our financial operations.

Funding of Grants:

Due to our improving financial viability the Foundation has been able to increase its overall funding of grants and in the year under review expended a total of \$1.1m.

A snapshot of the grants being funded is as follows:-

- (i) *Triennial Block Grant 2012 - 2015*
Titled Therapy & Molecular Genetics of Leukaemia in Infants amounting to \$1,0405,626
- (ii) *\$1M Recognition of Excellence Funding Grant 2013 - 2017*
Titled Molecular Genetics of Childhood Tumours amounting to \$1,000,000
- (iii) *CLCRF Fellowship Grant 2014 - 2016*
Titled Targeting Therapy and Disease Outcomes in Paediatric Cancers amounting to \$557,167
- (iv) *Woolworths WA Research Fellowship 2013 - 2015*
Titled Identifying the Molecular Abnormalities in Childhood Leukaemia amounting to \$400,000
- (v) *Midline Carcinoma Grant 2013 - 2014*
Titled Effective Therapies for NUT Midline Carcinoma amounting to \$113,135
- (vi) *Mopholino Therapy for Cancer Grant 2013 - 2014*
Titled The Molecular Genetic Landscape for Morpholino Therapies amounting to \$111,637

Again our congratulations and heartfelt appreciation is extended to Professor Ursula Kees and her dedicated team of researchers for their continued achievements both locally and internationally.

Telethon Kids Institute:

I am pleased to once again acknowledge the wonderful relationship we enjoy with the Telethon Kids Institute who administer and provide the necessary infrastructure for the Children's Leukaemia & Cancer Research Laboratory which we fund.

We extend our appreciation to both Professor John Carapetis, the Institute's Director, along with Tim McInnis, Head of Development, for continuing to enhance our partnership which gives true meaning to what the Institute espouses, and that is to 'Discover', 'Prevent', 'Cure'.

Professor In Paediatric Research:

The Foundation is pleased to have been invited by the Telethon Kids Institute to co fund, with the Cancer Research Trust, the establishment of a position for Professor/Senior Researcher in Paediatric Cancer Research to undertake the highest quality research into childhood cancers.

Our Foundation has agreed 'in principle' subject to finalising a funding agreement, to support the proposal as this will prove, in the fullness of time, to strongly reinforce our relationship with the Institute, enhance childhood cancer research and assist in the future stewardship of the CLCRF Research Laboratory.

Marketing Strategy & Development:

In my Report to members last year I foreshadowed the appointment of Kylie Dalton of Absolute Edge Media to create, manage and coordinate all of the Foundation's marketing, branding, promotion as well as identify and develop new community and media relationships.

Over the past 12 months Kylie has proven to be outstanding in her endeavours and has been re-appointed until 30th June 2015.

We are confident that Kylie's achievements in the initial stages of her appointment will continue to be enhanced resulting in even greater promotion of the Foundation as well as community relationships.

Community Activities:

Once again we are amazed at the wonderful and diverse support we receive from benefactors, businesses and the community at large.

Whilst such contributions will be individually acknowledged in our Executive Officer's Report I would pay particular mention of the wonderful contribution of the Rotary/Lions Bike Trek which this year raised the magnificent sum of \$62,727 and since its inception in 2004 has raised a total of \$526,795.

One of the more exciting events of the past year was the Keep the Flame Alive - Dance for a Cure followed shortly after by our World Record Attempt for the World's Longest Awareness Ribbon which raised in excess of \$52,000 and, of course, a place in the Guinness World Records.

I congratulate Kylie Dalton and the 'Keep the Flame Alive' committee, our own Foundation staff and the many volunteers who assisted in this wonderful event. I would also like to acknowledge that it is not just monies that are raised from these events but the awareness created which in turn initiates even greater support of our research endeavours.

To the many others who have supported our Foundation in varied and innovative ways throughout the past year please accept our grateful appreciation.

Governance Issues:

Over the past two years the Foundation has undertaken to address governance issues in particular with regulations with the new ACNC Act (Australian Charities & Not for Profit Commission) and the drafting of a new Constitution which requires updating after 30 years and compliance with the ACNC Act.

It is pertinent to note that the purpose of the ACNC is to set out a minimum standard of governance and to promote public trust and confidence in registered charities.

We are particularly indebted to Allion Lawyers who have gratuitously undertaken to oversee the drafting of a new constitution and to ensure compliance with all statutory authorities. We are also indebted to R Sceales & Company who are providing necessary advice regarding compliance with Public Ancillary Fund Guidelines.

It is expected that the drafts will be finalised and signed off by the ATO in the next two months and that an extraordinary general meeting of members will be called to adopt the new constitution.

Patron:

Justin Langer has proved on many fronts that he is a person of great integrity and has been an outstanding achiever in whatever he undertakes whether it is on the cricket field or as a proud and passionate family man.

We were extremely fortunate to have Justin accept the position of our first Patron and it is no surprise that he still holds this position. Notwithstanding his many commitments he has always given his support to the Foundation whenever called upon.

I am pleased to announce that Justin has agreed to continue in this role for the next 12 months.

Foundation Staff:

The Foundation is blessed to have competent and enthusiastic staff looking after our administrative needs.

To Andrea Alexander, Wendy Kearns and Kate Lush, I extend my personal appreciation for your loyalty and dedication as well as being wonderful ambassadors of the Foundation.

Committee of Management:

We are also blessed to have very dedicated and enterprising members on our Committee of Management, all of whom give willingly of both their time and expertise ensuring that our Foundation operates efficiently and effectively.

We were pleased to be able to fill a recent vacancy with John Vieira, a very successful financial advisor, who brings invaluable experience to the Committee of Management.

After 30 years Kim Williamson, who for the past decade, held dual roles as both Secretary and Treasurer of the Foundation stood down from Secretary and the Committee of Management appointed David Cattach to this position. Kim continues as our Treasurer.

I personally am extremely grateful to each and every member of the Committee of Management, they make my role as Chairman a pleasure.

Conclusion:

One of the more pleasing aspects of my role as Chairman is to witness at first hand the amazing growth of our membership base and the diversity and enterprise of all who contribute to the aims and objectives we espouse. To these wonderful persons, who represent the adage of 'people helping people' we extend our sincere appreciation and welcome you to the Foundation's 'family'.

To all the other wonderful community groups and individuals who support our funding strategies we are eternally grateful.

On behalf of Marie and myself I wish everyone a very Merry Xmas and a Happy New Year.



Geoffrey R Cattach AM
Chairman

I am pleased to report to the Members of the Children's Leukaemia & Cancer Research Foundation (Inc) for the financial year 2013/2014.

Corporate Benefactor

Wellard Group

The Wellard Group continued to support the Foundation with very generous donations totalling \$22,634. These funds consist of monies raised at their annual Xmas function (matched dollar for dollar by Wellard) and the Wellard 'Star of the West' Campdraft.

Benefactors

♥ Deceased Estates:

Beruldsen Margaret - VIC (final distribution)	\$11,671
Cahill Albert - NSW	\$9,835
Down Frank - WA	\$11,502
Findlay Lillias - WA	\$1,000
Henny Robert - WA	\$5,504
Jenkins Marjorie - NSW	\$32,240
McKendry William - WA - (est property value)	\$1,100,000
Lee John - WA	\$19,000
Lockyer Robert - VIC (final distribution)	\$119
McMahon Pauline - NSW	\$118,445
Marche Paul - WA	\$50,294
Vickery Gail - WA	\$182,831

The Foundation was not aware of some of these legacies until the benefactors had passed away.

♥ Tate Family Foundation - \$25,000

This donation represents the third year of the Tate Family's commitment towards the \$1M Recognition of Excellence grant.

♥ 2014 Kokoda Trek Team - \$13,644

Inspired by 9 year old cancer survivor, Shona Heard, six friends, John McDonald, Sandy Thompson, Sharon Bristow, Jacinta Pember and Leesa & Paul Hogarth took on the gruelling Kokoda Trail in April 2014 to raise funds for CLCRF.

♥ Cornerstone Lodge No 368 - \$10,000

The Cornerstone Lodge members raised \$5,000, which was then matched, dollar for dollar, by the Grand Lodge.

♥ Poker for Charity Association Inc - \$10,000

This donation was the last made by this organisation and its members. The association has since been wound up.

♥ Stan Perron Charitable Foundation - \$10,000

Mr Perron and his Foundation have been very charitable supporters of the Foundation since 1996.

♥ Phyllis M Ferguson - \$ 10,000

Mrs Ferguson is a dedicated supporter of the Foundation and its work.

To these individuals and organisations we extend our sincere thanks for their support of the Foundation. There were many others who have provided support and financial assistance during 2013/2014. Their generosity is greatly appreciated. Donations of \$100 and above are listed elsewhere in this report.

Keep the Flame Alive

The name 'Keep the Flame Alive' (KTFA) was created as a banner under which all Foundation organised events would be promoted. A second website was created for this purpose - www.keeptheflamealive.com.au

A KTFA team was formed with volunteers from the public and Foundation board representation. Without this team's tireless efforts, the KTFA events would not have happened. Particular acknowledgement of Kylie Dalton (Absolute Edge Media) - our Marketing & PR guru.

Two events were held in the year under review - Dance for a Cure and the Guinness World Record.

The Lord Mayor of Perth, the Hon Lisa-M Scaffidi and the City of Perth also provided considerable assistance.

♥ Dance for A Cure

On April 6, the 2014 Dance for A Cure was held in the Perth CBD at Forrest Place and the PCC. Over 1,000 people came together to 'dance for a cure'. This event, not only supported the Foundation but, encouraged fitness, with all ages, and experience levels, getting outdoors and having fun whilst being active.



The event was filmed by students from Central TAFE's live broadcasting team in the two different locations. Beverley Margaret School of Dance took on the challenge to choreograph the event. All of the moves were filmed and uploaded to the website for those registering to learn.

The dance school also auditioned ladybug dancers between the ages of six and eight as well as choreographed the lyrical dance performance.

The event also introduced the KTFA song to the general public for the first time. The song had been written specifically for the event by local singer/songwriter Rose Parker.

The production of the song saw more than 20 talented musicians from around Perth, including Graham Wood – founder of The Ellington Jazz Club, come together to produce the inspirational song.

A total of \$52,000 was raised from registrations, donations and sponsorship.

Guinness World Record

The Foundation joined forces with WA schools and community organisations to achieve the Guinness World Record for the Longest Awareness Ribbon.

Early in 2014 the Foundation worked with schools to sign segments of the yellow ribbon with get well messages for sick children. A total of 66 schools participated, many of which also raised funds for the Foundation.

All the ribbon pieces were then sewn together by the dedicated ladies of the Busy Fingers Sewing Club, to reach a world record breaking length.

The ribbon was officially unfurled on Saturday 19 April at Langley Park in the City of Perth. Many volunteers helped to lay it out in the traditional awareness ribbon shape, which was then photographed from the air.

The final length of 1,940 metres was confirmed by our official measurer, Simon Treasurer, from AAM Group. This length beat the previous world record by 693 metres (held by the Aid & Hope Program for Cancer Patient Care Palestine in Gaza in 2012 of 1,247 metres).

Considerable documentation was then sent to Guinness World Records and on the 1st October, official advice was received that the Foundation now holds the World Record for the Longest Awareness Ribbon.

Tele-Marketing Raffles

There were three raffles completed during the year ending June 2014. Revenue from these raffles totalled \$542,129 which, after expenditure resulted in a surplus of \$192,731. Donations received via the raffles are included in the revenue figure.

Although the surplus figure was down compared with last year, it must be noted that there are many other charities now utilising this type of fundraising. Our raffles still help to increase our profile in the community around Australia. CLCRF have 184,000+ supporters on the raffle database with 12% of these currently active.

The Royal Life Saving Society WA (RLSWA), through its call centres in Manjimup and Bridgetown, continue to undertake our telemarketing calls and the Hello Call Centre look after the administration of the raffle funds.

These raffles are on a cost recovery basis and RLSWA make no profit from the Foundation's raffles.

Donation Appeal Campaigns

From each raffle campaign the Foundation has been able to establish a database of donors in addition to raffle supporters. Tax and Xmas donation appeals were sent to the donor database in 2013/14. A letter of appeal was also sent to a select number of donors from the Foundation database for the tax appeal.

All three campaigns were successful and represent an effective complimentary fundraising program to the raffles. Net cash received from the campaigns was \$105,814. It is worth noting that the appeal/s letter used a new layout for the pledge slip. From this new design there was a 16% increase in donations received. These campaigns were sent to approximately 6,000 supporters.

2013 South West Bike Trek

The Foundation's 11th South West Bike Trek kicked off in Mandurah on Monday the 14th October and finished in Augusta on Saturday the 19th. This year there were approximately 25 riders per day.

This event would not be possible without the support of the many service clubs, shires, companies and individuals. A total of \$62,727 was raised from the 2013 trek.



Foundation Update

Only one edition of the Foundation Update was published during the period under review. The creation of this newsletter was made possible with the generous support of Bob and Jan Fawcett of Ultra Printing, Marketing and Publishing Services.

2014 Family Concert

Due to unforeseen difficulties, the 2014 Family Concert was not held. It was felt that we did not want our supporters to attend a sub-standard event. Meetings have been held with Houghton Winery, and the new caterers, and the date of Saturday 21 March has been set for next year.

Website

www.childcancerresearch.com.au

Our website continues to be visited by people from around the world and is a very useful tool in building our profile in the community at large. We would like to acknowledge Phil Solomon, of Topshelf, who maintains our web site at no cost to the Foundation.

The CLCRF website will be revamped in the near future to make it more user friendly and provide more up to date information. The site will then be administered by the CLCRF office.

Social Media

www.facebook.com/CLCRF

The CLCRF facebook page has increased in profile with currently 2,457 likes. The majority of our 'likers' are from Australia, then the USA, followed by UK, New Zealand, Philippines, Indonesia, Malaysia, South Africa, India and Ireland.

facebook.com/flamealive

The KTF facebook page also has 2,466 likes. With a similar distribution of 'likers' from Australia, then France, UK, USA, New Zealand, Philippines, Canada, Brazil, Indonesia and India.

twitter.com/CLCRF

We currently have 89 followers on Twitter. The Twitter account is mainly used when at events eg Dance For A Cure, Swan River Run, PwC Cool Night Classic.

These social media platforms have proved to be of great benefit to the Foundation.

Membership

At the time of writing this report we have 609 members. Although we have had new members sign up during the past year, some of our existing members have passed away.

Fund Raising Platforms

Support for the Foundation has continued to come from many people around Australia. CLCRF's fundraising profile continues to be strong via the online fundraising entities such as Everyday Hero, Go Fundraise and My Cause. Funds raised via these platforms totalled \$42,045 during 2013/14. These third party fundraising platforms are an excellent way for people to support the cause.

School/College Support

The Foundation again saw continued support from schools and colleges around Australia. It is heart-warming to acknowledge 'children helping children'. Particular mention must be made of Christ Church – Romsey House, who have supported the Foundation since the late 1980's.

Conclusion

The Foundation has now been in its new 'home' for three years. Over the past year we have had a number of small functions and we have also welcomed other charitable organisations who have made use of our board room facility. We feel this is an essential part of being part of the not-for-profit community – charities helping each other.

In March 2014 Wendy and I attended the Fundraising Institute of Australia's international conference in Melbourne. For not-for-profit organisations, attendance at these conferences is essential to stay in touch with the industry and to network with peers. Wendy and I thank the Committee for their support of this professional development.

Thank you to my Executive Assistant, Wendy Kearns and our Administrative Assistant, Katelyn Lush for their tireless efforts during the past year. I have truly appreciated the wonderful support from them both.

Our Board of Management continue to provide me with support and guidance. It is an honour to work for such a dedicated group of people.

I would like to take this opportunity to wish everyone a very Merry Christmas and a safe and peaceful 2014.

Andrea Alexander
Executive Officer



Triennial Block Grant (2013 - 2014). Professor Ursula R Kees

Title: Therapy and Molecular Genetics of Leukaemia in Infants



Babies diagnosed with leukaemia face a dismal outlook. This is in sharp contrast with leukaemia in children who are older than 12 months at the time of diagnosis. Some of them achieve a 5-year survival of 95%. Strikingly, in leukaemia patients less than 3 months at the time of diagnosis, the survival rate is only 30%. In an attempt to find better therapy for these patients, international study groups conducted many studies, and the babies were given more intensive therapy. Unfortunately, this led to a large number of toxic deaths, and did not improve overall survival. We urgently need to find novel therapy for these patients. Since treatments using highly toxic chemotherapies are not successful, understanding the biology of this disease holds the key.

In this study, we investigated the genetic features of the leukaemia cells from babies. We have performed genetic analyses using state-of-the art next generation sequencing technology, referred to as RNA-sequencing and exome sequencing. We gained novel insight into which genes are involved, their contribution to disease progression and drug resistance. We confirmed that a gene called MLL is not in its normal position on the chromosome, but is translocated, such that it is next to another chromosome. These translocations are known to confer poor prognosis for patients. We also found that infant patients inherited extremely rare versions (called polymorphisms) in other genes that are known to play a role in cancer. Importantly, these molecular studies identified several known cancer-causing genes, as well as changes to other genes. Many of these altered genes can be targeted by modern therapies to improve treatments of patients with infant leukaemia.

We used the leukaemia specimens from the patients to generate cell lines, such that the cells can be kept alive in the laboratory, which in turn allows us to do study which drugs may be killing the leukaemia cells. We have generated a panel of eight cell lines and used the same methods to analyse the genetic features as were used on the cells from the patients. This confirmed that the cell lines showed the identical translocations of the MLL gene as the ones found in the leukaemia cells from the patients. We then screened the panel of cell lines against 150 approved cancer drugs, which is the first comprehensive assessment that examined the drug response in leukaemia cells from babies.

The information obtained clearly showed that some of the currently used drugs do not kill the leukaemia cells (e.g. Mercaptopurine and Methotrexate), while others were very effective, yet not used in contemporary protocols for patients (e.g. Romidepsin and Bortezomib). Importantly, we could show that these drugs enhance the effectiveness of drugs that are currently used in the treatment of leukaemia patients, for example Cytosine Arabinoside. Taken together, these studies have identified drugs that could be useful to treat babies with leukaemia, including established anti-cancer drugs as well as new-generation drugs.

These drugs are expected to provide great benefits in the treatment of patients with this disease. We continue our studies to determine how best to combine particular drugs, and examine outcomes in experimental models. Our results have been presented to members of the international study group Children's Oncology Group and they intend to include our findings in the plans for the next clinical trials.

These and other studies have generated a number of research publications and have allowed us to leverage additional government funding to support the work. These details are provided below:

Additional Funding Leveraged:

- The Kid's Cancer Project Grant (2014): Improving the treatment for infants with leukaemia (Kees UR, Cruickshank, M, \$100,000).
- NHMRC Project Grant ID1011499 (2011-2015): Targeting drug-resistance in childhood leukaemia (Kees UR, Lock RB, Beesley AH, \$626,732).
- NHMRC Project Grant ID1007586 (2011-2014): The role of connective tissue growth factor in the pathobiology of lymphoid tumours and response to therapy (Kees, UR, Beesley AH, Charles AK, \$601,732).

Recent Publications:

- Kotecha RS, Kees UR, Cole CH and Gottardo NG, 2014. Rare childhood cancers, an increasing entity – the need for global consensus and collaboration. Submitted to Cancer Medicine.
- Welch MD, Howlett M, Halse HM, Greene WK and Kees UR, 2014. Novel CT domain-encoding splice form of CTGF/CCN2 expressed in B-lineage acute lymphoblastic leukaemia. Submitted to British Journal of Haematology.
- Richmond J, Hernan C, Evans K, High L, Mendomo A, Robbins A, Meyer C, Venn NC, Marschalek R, Henderson M, Sutton R, Kurmasheva RT, Kees UR, Houghton PJ, Smith MA and Lock AB, 2014. Effective targeting of the P53/MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Submitted to Clinical Cancer Research.
- Cruickshank MN, Ford J, Anderson D, Kotecha R, Cole C, Kees UR, 2014. Pharmacological and molecular analysis of MLL-rearranged infant acute lymphoblastic leukaemia. To be submitted December 2014.
- Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung L, Samuels AL, Crook M, Charles AK, Cole CH and Kees UR, 2014. Secretion of connective tissue growth factor (CTGF/CCN2) in acute lymphoblastic leukaemia leads to increased extracellular matrix synthesis and reduced survival in vivo. To be submitted December 2014.
- Gout A, Cruickshank MN, Kotecha R, Kees UR, 2014. Characterization of rare alleles in MLL-rearranged infant acute lymphoblastic leukaemia by transcriptome sequencing. To be submitted January 2015.
- Samuels AL, Heng JA, Beesley AH and Kees UR, 2013. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 2014. 165:57-66.
- Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, Arndt G, Charles AK, Cole CH and Kees UR, 2013. Comparative drug screening in NUT midline carcinoma. British Journal of Cancer, 2014.110(5):1189-98.
- Kotecha RS, Gottardo NG, Kees UR and Cole CH, 2014. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer Journal (2014). 4.10.1038/bjc.2014.17.
- Wells JE, Cole CH and Kees UR, 2014. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. International Journal of Cancer, 2014 May. doi : 10.1002/ijc.28972.

Cheung CT, Strickland DH, Howlett M, Ford F, Charles AK, Lyons KM, Brigstock DR, Goldschmeding R, Cole CH, Alexander WS and Kees UR, 2013. Connective tissue growth factor is expressed in bone marrow stromal cells and regulates IL-7 dependent B lymphopoiesis. *Haematologica*, 2014.99(7):1149-1156.

Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR and Lock RB, 2014. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. *Blood Cancer J*. 2014 Aug 1;4:e232. doi:10.1038/bjc2014.52.

De Kock N, Sabbaghian, H, Druker E, Weber N, Hamel S, Miller CS, Choong S, Gottardo NG, Kees UR, Rednam SP, Van Hest L, Jongmans MC, Zacharin M, Bouron-Dal Soglio D, Malkin D, Priest JR, Perry A, Albrecht S, Grundy RG and Foulkes WD, 2014. Germ-line and somatic DICER1 mutations in pineoblastoma. *Acta Neuropathol*. 2014 Oct; 128(4):583-95. doi: 10.1007/s00401-014-1318-7.

Longville BAC, Anderson D, Welch MD, Kees UR and Greene WK, 2014. Aberrant expression of aldehyde dehydrogenase 1A (ALDH1A) subfamily genes in acute lymphoblastic leukaemia is a common feature of T-lineage tumours. *Br J Haematol*. 2014 Sep 11;doi: 10.1111/bjh.13120.

Hooper CM, Hawes SM, Kees UR, Gottardo NG and Dallas PB, 2014. Gene expression analyses of the spatio-temporal relationships of human medulloblastoma subgroups during early human neurogenesis. *PLoS ONE* 9(11): e112909. doi:10.1371/journal.pone.0112909

Welch MD, Greene WG and Kees UR, 2013. Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemia. *British Journal of Haematology*, 2013, 162(4):537-41

Beesley AH, Firth MJ, Anderson D, Samuels AL, Ford J and Kees UR, 2013. Drug-gene modelling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcome. *Cancer Research*, 2013, 73(9):2749-59.

Bailey HD, deKlerk NH, Fritsch L, Attia J, Daubenton JD, Armstrong BK, Milne E et al. AUS-ALL Consortium: Refuelling of vehicles, the use of wood burners and the risk of acute lymphoblastic leukaemia in childhood. *Paediatric and Perinatal Epidemiology*, 2011, 25: 528-539.

Reid A, Glass DC, Bailey HD, Milne E, deKlerk NH, Downie P, Fritsch L et al. AUS-ALL Consortium, Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to extremely low frequency electromagnetic fields. *British Journal of Cancer*, 2011. 105:1409-1413

Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, Gottardo NG, Cole CH and Kees UR. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. *Leukemia Research* 2012, 36: 299.

Kotecha RS, Ford J, Beesley AH, Anderson D, Cole CH and Kees UR. Molecular characterization of identical, novel MLL-EP515 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. *Haematologica* 2012 .97(9):1447-50.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, Kees UR and Beesley AH. FusionFinder: a software tool to identify expressed gene fusion candidates from RNA-Seq data. *PLoS One* 2;7(6):e39987.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR and Beesley AH. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. *Oncogene*, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR, Beesley AH. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. *Oncogene* 2013;32(39):4664-74.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, Kees UR, Beesley AH, 2012. FusionFinder: A tool to identify expressed gene fusion candidates from RNA-Seq data. *PLoS One* 7(6):e39987

Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, Gottardo NG, Cole CH and Kees UR. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. *Leukemia Research* 2012, 36: 299.

CLCRF Research Fellowship (2010 - 2013; 2013 - 2016)

Associate Professor Alex H Beesley

Title: Targeting Therapy and Disease Outcomes in Paediatric cancer

Dr Beesley has been employed within the CLCRF Laboratory in the Division of Cancer and Leukaemia Research since 2003, and was awarded the inaugural CLCRF Research Fellowship in July 2010.

This three-year Fellowship provided support for Dr Beesley to conduct research to investigate the ways in which patients with leukaemia become resistant to certain therapies, in particular steroids such as dexamethasone. This class of drugs is one of the most important for the treatment of the disease and yet some patients develop resistance, which can lead to relapse. Our studies using bone marrow cells from leukaemia patients (grown in the test tube to generate cell lines) have helped us to identify some of the mechanisms associated with the development of steroid resistance.

This includes specific changes to the metabolism of the cancer cells, which alters the way in which they use nutrients, for example sugar. We have been investigating these changes in greater detail using modern biochemical methods at the University of Western Australia, and also collaborating with researchers at the Children's Cancer Institute Australia in Sydney to identify new drugs that may be used to overcome steroid resistance in patients who have relapsed.

A second part of this study was the development of 'biomarkers' that can help in the early identification of leukaemia patients that are at risk of relapse. To achieve this we have studied the gene profiles of a group of patients and identified particular patterns that are predictive of good or inferior clinical outcome. The accurate identification of patients at risk of relapse can improve treatment protocols for patients, tailoring the amount of therapy they receive to their level of risk. This improves not only cure rates, but also minimises secondary side effects of chemotherapy. In addition these gene models have identified drugs that may be of particular benefit in certain patient groups.

In 2013, Dr Beesley was successful in renewing his Fellowship, with the aim of conducting research into a rare type of cancer called NUT midline carcinoma (or NMC). This is a terribly aggressive cancer that can affect children of all ages, and there is currently no cure. Patients are treated with aggressive chemotherapy and surgery but survival is typically less than one year. The first report of this rare disease was published by Professor Kees in 1991, and we continue to be one of very few laboratories in the world studying its biology. Thanks to the funding provided from the CLCRF, we have been able to obtain material from investigators and tumour banks around the world to generate a unique panel of NMC cell lines here in Perth. Using this comprehensive panel we have started testing for drugs that might be more effective at killing the cancer cells, and we have also sent the samples to have their entire genetic code analysed, the first time that this has been done for this disease. This information will provide a blueprint



of what goes wrong in NMC cells and the types of drugs that might be best for treatment. In 2013 he was awarded two CLCRF Project Grants to further support this NMC research, and details of these projects are provided below.

As part of his Fellowship he has co-written two successful NHMRC Project Grant applications together with Professor Kees and has applied to the NHMRC for additional funding to support the NMC research program. He has published 11 journal articles during his Fellowship and has been responsible for presenting research from the laboratory to community groups and scientific audiences, both in Australia and overseas, acknowledging the support from the CLCRF at each opportunity.

Findings from research conducted during Dr Beesley's Fellowship have been presented in the following scientific forums and community groups:

- The IVEC Supercomputing Annual Symposium, Perth, Western Australia (2014).
- EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain (2014).
- The European Association for Cancer Research Conference, Cambridge, UK (2013)
- The 'Beyond the Genome' Conference, San Francisco, USA (2013).
- The American Society for Human Genetics, Boston, USA (2013).
- The Australian Society for Biochemistry and Molecular Biology (ASBMB) Annual Symposium, Fremantle, WA (2012, 2014).
- 4th New Directions in Leukaemia Research Conference, QLD (2012).
- New Directions in Child and Adolescent Health Symposium, Princess Margaret Hospital (2012).
- Children's Cancer Institute Australia (CCIA), Sydney (2012).
- The Lorne Cancer Conference, Victoria (2012, 2013).
- 28th Annual Genes & Cancer Meeting, Warwick, UK (2011).
- Keystone Symposium 'Omics Meets Cell Biology', Alpbach, Austria (2011).
- The Perth Cancer Club, WAIMR (2011).
- The Cancer Council WA Symposium, Perth, WA (2011 & 2013).
- The Lowy Symposium: Discovering Cancer Therapeutics, Sydney (2013).
- Rotary-Lions Club South West Bike Trek Fundraiser Dinner, Pinjarra (2012, 2013, 2014).

Together these studies have generated a number of important research publications and have allowed us to leverage additional funding to support the work:

Additional Funding Leveraged:

- NHMRC Project Grant ID1011499 (2011-2015): Targeting drug-resistance in childhood leukaemia (Kees UR, Lock RB, Beesley AH, \$626,732).
- NHMRC Project Grant ID1007586 (2011-2014): The role of connective tissue growth factor in the pathobiology of lymphoid tumours and response to therapy (Kees, UR, Beesley AH, Charles AK, \$601,732).
- CLCRF Research Fellowship (2013 - 2016): 'Targeting therapy and disease outcomes in NUT Midline Carcinoma' (Beesley AH, \$557,167).
- CLCRF Project Grant (2014): 'Morpholino Therapy for Childhood Cancer' (Beesley AH, \$113,135 over 1 year).
- CLCRF Project Grant (2014): 'Finding the Most Effective Therapies For Midline Carcinoma' (Beesley AH, \$111,637 over 1 year).

CLCRF Project Grant (Jan 2014 - Dec 2014) Associate Professor Alex H Beesley

Effective Therapies for NUT Midline Carcinoma

NUT Midline Carcinoma (NMC) is a terribly aggressive cancer affecting both children and adults alike, and for which survival is typically less than one year. There is currently no cure for NMC and yet we know from our experience with childhood leukaemia that cures for apparently fatal cancers can be developed. Current treatments for NMC have essentially been adapted from those used in other cancers but this approach clearly is not working. There are a large number of 'conventional' chemotherapy drugs available for doctors to treat such patients, but to date there has been no evidence to guide them as to which might be the most effective. There is also growing evidence that some drugs used in non-cancer diseases (e.g. metabolic disorders), may be effective against tumours.

Thanks to the support of the CLCRF, we have now expanded what was originally a small collection of three NMC cell lines derived from patients treated at Princess Margaret Hospital, to a total of 11 such cell lines – to our knowledge, the most comprehensive collection of NMC cell lines in the world. By studying these lines we have learnt that NMC is comprised of at least five distinct genetic subtypes, and this is likely to have important implications for drug therapy and clinical outcomes. In preliminary studies we tested a subset of these cell lines against a large number of conventional and novel drugs and identified the types of drug that seemed to be most effective. In collaboration with the Children's Cancer Institute in Sydney, we are now using the extended NMC cell line panel to further refine these findings. The initial data from this screen has already revealed some surprising results, in that certain drugs that were thought to be highly effective in this disease are apparently not effective in every NMC subtype. This has important clinical ramifications since this drug class is now in clinical trial for NMC. The data also support our previously published work suggesting that the drug flavopiridol may be an attractive chemotherapy in this disease, since it has so far proven to be effective in all NMC cell lines tested. Over the next 12 months we will therefore confirm exactly which drugs and drug classes are most effective against these cancer cells. We will also study potential mechanisms of resistance to flavopiridol in cancer cells using a model system that we have established in the laboratory over the last few years.

Finally, we will also investigate how some of these drugs, rather than just through simple toxicity, also affect the way the cancer cells grow and mature. These data will be integrated with the genetic studies to help identify the key biological pathways driving this dreadful disease and the most promising therapy approaches.

CLCRF Project Grant (Jan 2014 - Dec 2014) Associate Professor Alex H Beesley

Morpholino Therapy for Childhood Cancer

Patients with NUT midline carcinoma (NMC) share a common genetic feature, which is a specific re-arrangement of the DNA within the cancer cell. Whilst this abnormality contributes to driving the disease, it also represents an Achilles heel because it can be used as a 'target' to design specific therapies i.e. drugs that attack the cancer cell but leave healthy cells alone. In 2014 we worked with Prof Steve Wilton from Murdoch University to develop a novel therapy designed to target this genetic abnormality. His approach is to use drugs called 'morpholinos' that interfere with the way genes are expressed in the cell, and he has successfully pioneered this approach as a genetic therapy in the field of muscular dystrophy. We wished to develop this as a therapy approach for NMC, but our findings this year have demonstrated that this is unlikely to be successful without significant further investment. However, the use of these agents has revealed unexpected information about the ways in which the NMC gene can be expressed. Specifically, we have managed to induce a new variant of the NMC gene that can be expressed under certain conditions. Remarkably, in a patient recently diagnosed at Sydney's Children's Hospital we were able to confirm this variant as an independent clinical subtype and we are currently trying to make a cell line with which to further study its biology.

With this discovery we now know that there are at least five distinct molecular subtypes of NMC, as defined by the structure of this particular genetic feature, and we also know that they respond differently to chemotherapy drugs. However, we do not yet understand the full biological significance of these different subtypes, nor what determines these drug sensitivities. To unravel this question we have started sequencing the full genetic code of our NMC cell lines and patient specimens. Over the next few months we will be able to analyse this information to identify the critical features driving the disease and perform laboratory experiments in our panel of cell lines to validate these findings. This approach will be integrated with drug-sensitivity data to yield a comprehensive map of the molecular genetic landscape of NMC and the biological pathways that are the most promising as targets for future therapies.

Publications: A/Prof Beesley (2011 – 2014):

Carter T, Charles AK, Murch AR, Beesley AH, Kees UR. A retrospective review of NUT-midline carcinoma prevalence at a Western Australian Paediatric Hospital (Anticipated submission Feb 2015).

Beesley AH*, Samuels AL*, Yadav BD*, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia

[*Joint first-authorship]. *Blood Cancer J* 2014;4:e232.

Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Faires TW, Arndt G, Charles AK, Cole CH and Kees UR. Comparative drug screening in NUT-midline carcinoma. *Br J Cancer* 2014;110(5):1189-98.

Samuels AL, Heng J, Beesley AH, Kees UR. Bioenergetic modulation sensitises acute lymphoblastic leukaemia cells to glucocorticoids. *Br J Haematol* 2014;165(1):57-66.

Beesley AH, Firth MJ, Anderson D, Samuels AL, Ford J, Kees UR. Drug-gene modeling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcome. *Cancer Res* 2013;73(9):2749-59.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR, Beesley AH. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. *Oncogene* 2013;32(39):4664-74.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, Kees UR, Beesley AH (2012). FusionFinder: A tool to identify expressed gene fusion candidates from RNA-Seq data. *PLoS One* 7(6):e39987

Kotecha RS, Ford J, Beesley AH, Anderson D, Cole CH, Kees UR (2012). Molecular characterization of identical, novel MLL-EP515 translocations and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. *Haematologica*. Sep;97(9):1447-50.

Woolworths Research Fellowship (2012 – 2015)

Dr Mark N Cruickshank

Identifying Molecular Abnormalities in Childhood Leukaemia to Improve Treatment

Dr Cruickshank has been employed within the CLCRF Laboratory in the Division of Cancer and Leukaemia Research since 2012, and was awarded the Woolworths CLCRF Research Fellowship. This Fellowship has enabled Dr Cruickshank to conduct research aimed at (1) identifying novel drugs for the treatment of high-risk infant leukaemia patients and (2) genetic mechanisms underpinning disease. Dr Cruickshank has also continued researching genetic determinants of paediatric leukaemia and drug resistance. As part of his Fellowship, Dr Cruickshank has been involved in experimental design, data analysis and manuscript preparation for projects on infant ALL and childhood ALL, detailed under the CLCRF Triennial Block Grant. The long-term vision of these research aims are toward detection of genetic biomarkers that are predictive of drug responses, thus empowering clinicians with new molecular prognostic tests and novel drugs, to design personalised therapies to cure this disease.

While many types of childhood leukaemia have shown remarkable improvements in patient survival (now up to 95%) over the last twenty years, infant leukaemia remains challenging to treat with low survival (~30%) of the very young patients and significant morbidity for survivors. Our drug screening studies have utilised patient specimens and cell lines grown in test tubes derived from these leukaemia samples. In collaboration with the Children's Cancer Institute Australia, we have interrogated the efficacy of over 150 novel drugs including FDA-approved cancer chemotherapies and additional "targeted" therapeutics that are currently in clinical trials for biologically related cancer sub-types. These drugs represent the "next-generation" of



therapeutics that are designed to target vulnerabilities specific to cancer and therefore are less toxic against normal cells with reduced patient side effects. In addition, we have examined the interaction of selected novel drugs and current backbone therapies. Indeed, any novel drugs that are progressed to the clinic are likely to be introduced in such combinations. We have identified specific drug combinations that function synergistically, but have also identified drug combinations that, in some patients, show adverse interactions. Therefore, we have been able to demonstrate that some drug combinations are consistently effective in killing infant leukaemia cells, while other drug combinations interact adversely to reduce their efficacy in some patient leukaemia cells. These results have been presented to members of the Children's Oncology Group for consideration of therapies to be included in clinical trials.

Our genetic characterisation of infant leukaemia has utilised state-of-the art "genomic" technologies, providing comprehensive characterisation of genetic differences specific to infant leukaemia patients. Indeed, the genetic cause of infant leukaemia has remained elusive, even though genomic sequencing technologies has identified many genes driving paediatric and adult cancers. Dr Cruickshank has been testing the hypothesis that inherited gene mutations from both parents are necessary to drive disease, even though these gene mutations do not cause disease in each of the parents. Moreover, these gene mutations are found in both the leukaemia cells as well as healthy cells of the patient.

We have identified an increased number of "defective" genes in infants with leukaemia compared to healthy individuals. Indeed, among the "defective" genes found in infant leukaemia patients, many are known to act as cancer driver genes in paediatric and adult cancer patients.

The unique resources, including patient specimens and cell lines generated within the CLCRF Laboratory, are also being used to identify specific genes that are altered in infant and childhood leukaemia and which may confer resistance to conventional therapies. These studies have identified potential 'biomarkers' that could predict drug sensitivity or drug resistance. The 'biomarkers' under investigation include gene mutations, and alterations in chromosomes and levels of gene-expression.

Dr Cruickshank's work on paediatric leukaemia has identified a class of enzymes that may be involved in resistance to the drug flavopiridol. Using leukaemia cells selected for drug resistance, "genomic" analyses identified mutated genes that encode enzymes that process flavopiridol. Furthermore, analysis of gene expression induced by flavopiridol, identified enzymes involved in neutralizing and eliminating drugs that were activated after drug treatment. Taken together, these results have defined genes that may represent 'biomarkers' of drug resistance and targets for therapy in drug-resistant leukaemia.

Dr Cruickshank has presented research from the Laboratory to community and scientific audiences in Australia, acknowledging the support from the CLCRF at each opportunity. Findings from research conducted during Dr Cruickshank's appointments have been presented in the following scientific forums and community groups:

- Telethon Kids Institute; Discussion and Technical Seminar Series, Perth (2014)
- Children's Leukaemia & Cancer Research Foundation meeting (2014)
- Australian Bioinformatics Conference (2014)
- The 'Beyond the Genome' Conference, San Francisco, USA (2013).
- The American Society for Human Genetics, Boston, USA (2013).
- Cancer Epigenomics Cell Symposium, Sitges, Spain (2013)
- Telethon Institute for Child Health Research Seminar, Perth (2013)
- Perth Cancer Club, Perth (2013)
- Children's Leukaemia & Cancer Research Foundation meeting (2013)
- Lorne Genome (2013)
- WA Genomics & Epigenomics interest group, UWA, Perth (2012)

Publications Dr Cruickshank (2011 – 2014):

Cruickshank MN, Ford J, Anderson D, Kotecha R, Cole C, Kees UR: Pharmacological and molecular analysis of MLL-rearranged infant acute lymphoblastic leukaemia. 2014 Manuscript in preparation for Leukemia.

Gout A, Cruickshank MN, Kotecha R, Kees UR: Characterization of rare alleles in MLL-rearranged infant acute lymphoblastic leukaemia by transcriptome sequencing. 2014 Manuscript in preparation for PLoS Genetics.

Cruickshank MN, Mason R, Fenwick E, Karimi M, Abraham LJ, Ulgiati D: Notch signaling regulates activity of the human Complement receptor type 2 (CR2/CD21) gene. 2014 Manuscript in preparation for Cellular Signalling.

Cruickshank MN, Dods J, Fenwick E, Karimi M, Rae A, Holers VM, Abraham LJ, Ulgiati D: Tandem E-box motifs control human Complement receptor 2 (CR2) promoter activity via RP58, E2A, USF proteins and localized chromatin accessibility. 2014 Manuscript in preparation for The International Journal of Biochemistry and Cell Biology.

Cruickshank MN, Oshlack A, Theda C, Davis PG, Martino D, Sheehan P, Dai Y, Saffery R, Doyle LW, Craig JM: Analysis of epigenetic changes in survivors of preterm birth reveals the effect of gestational age and evidence for a long term legacy. *Genome Medicine* 2013, 5:96.

Martino D, Loke YJ, Gordon L, Ollikainen M, Cruickshank MN, Saffery R, Craig JM: Longitudinal, genome-scale analysis of DNA methylation in twins from birth to 18 months of age reveals rapid epigenetic change in early life and pair-specific effects of discordance. *Genome Biology* 2013, 14:R42.

Jablensky A, Angelicheva D, Donohoe GJ, Cruickshank MN, Azmanov DN, Morris DW, McRae A, Weickert CS, Carter KW, Chandler D, et al: Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia. *Molecular Psychiatry* 2012, 17:1328-1339.

Cruickshank MN, Pitt J, Craig JM: Going back to the future with Guthrie-powered epigenome-wide association studies. *Genome Med*, 2012, 4: 83.

Gordon L, Joo JE, Powell JE, Ollikainen M, Novakovic B, Li X, Andronikos R, Cruickshank MN, Conneely KN, Smith AK, et al: Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. *Genome Research* 2012, 22:1395-1406.

Cruickshank MN, Karimi M, Mason RL, Fenwick E, Mercer T, Tsao BP, Boackle SA, Ulgiati D: Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21). *Molecular Immunology* 2012, 52:165-173.



Children's Leukaemia & Cancer Research Foundation (Inc)
Financial Statements Year Ended June 30 2014
ABN: 42 030 465 053



**CHILDREN'S
Leukaemia &
Cancer Research
Foundation (Inc.)**

Suite 3
100 Hay Street,
Subiaco WA
PO Box 1118
West Perth WA 6872

Telephone
(08) 9363 7400

Fax
(08) 9382 8798

Email
admin@
childcancerresearch.
com.au

Web
childcancerresearch.
com.au

ABN 42 030 465 053

Patron

Justin Langer

Life Members

Geoff R Cattach AM
Peter J Harper
Peter Falconer OAM
Phil Bruce

STATEMENT BY THE COMMITTEE OF MANAGEMENT

The Committee Members have determined that the Foundation is not a reporting entity, and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial report.

In the opinion of the Committee of Management, the accompanying financial reports:

1. (a) The accompanying Operating Statement gives a true and fair view of the surplus of the Foundation for the financial year; and
(b) The accompanying Balance Sheet gives a true and fair view of the state of affairs of the Foundation as at the end of the financial year.
2. At the date of the statement there are reasonable grounds to believe that the Foundation will be able to pay its debts as and when they fall due.

This statement is made in accordance with a resolution of the Committee of Management and is signed by and on behalf of the Committee of Management by:

.....
Executive Officer – Andrea Alexander

.....
Treasurer – Kim Williamson

Date: 18/11/2014

INDEPENDENT AUDIT REPORT

To: The Management Committee, Children's Leukaemia & Cancer Research Foundation (Inc)

SCOPE

We have audited the Financial Report for the Children's Leukaemia & Cancer Research Foundation (Inc) for the year ended 30 June 2014. The Management committee is responsible for the Financial Report.

Our audit has been conducted in accordance with Australian Accounting Standards. Our procedures include examination on a test basis, evidence supporting and other disclosures in the Financial Report. These procedures have been undertaken to form an opinion whether, in all material aspects, the Financial Report is fairly presented.

The audit opinion expressed in the report has been formed on the above basis.

QUALIFICATION

As is common with organizations of this type, it is not practical for Children's Leukaemia & Cancer Research Foundation (Inc) to maintain an effective system of internal control over donations and other fund raising activities until their entry in the Accounting Records. Accordingly our audit in relation to fund raising was limited to the amount recorded.

QUALIFIED AUDIT OPINION

In our opinion, except for the effect of such adjustments, if any as might have been determined necessary had the limitation discussed in the qualification paragraph not existed, the Financial Report presents fairly and in accordance with applicable Accounting Standards, the financial position of Children's Leukaemia & Cancer Research Foundation (Inc) at 30 June 2014.

AUDITOR

Signature



Full Name

Nick Del Popolo, ACA

Address

9 Carrington Street, North Perth, WA, 6006

Phone

0419 922 776

Date

19.11.2014

Liability limited by a scheme approved under professional standards legislation.

Children's Leukaemia & Cancer Research Foundation (Inc.)
Operating Statement
For the period 01/07/13 - 30/06/14

REVENUE	2013/2014	2012/2013
Subscriptions	1,983	5,995
Donations & Promotions	128,847	135,551
Community Activities	259,278	311,100
Raffles & Direct Mail Campaigns	649,674	803,692
Schools & Associations	7,706	6,470
Commercial Support:		
Triple Vend/Austway	5,125	14,050
United Fundraisers	1,867	2,850
VLT	1,654	2,596
Woolworths	-	408,549
Grants & Bequests:		
Bequests (property value)	1,555,940	716,518
3BL (Brain Tumour Research Project)	2,478	1,827
Interest Received	<u>229,832</u>	<u>253,621</u>
TOTAL REVENUE	<u>\$ 2,844,383</u>	<u>\$ 2,662,819</u>
EXPENDITURE:		
Admin/Salaries & Other Costs	317,886	389,248
Raffles & Direct Mail Campaigns	351,398	486,309
Promotions & Events	120,982	69,921
Block Grant Funding/Grants:		
Block Grant Allocation	430,151	395,581
1Mio Grant of Excellence	220,598	129,435
CLCRF Fellowship	159,154	141,265
Woolworths Fellowship	112,128	85,777
Three Boys Legacy		3,586
Midline Carcinoma Grant	29,580	
Morpholino Therapy for Cancer Grant	49,357	
Property Outgoings/Refurbishment	29,189	26,055
TOTAL EXPENDITURE	<u>\$ 1,820,423</u>	<u>\$ 1,727,176</u>
EXCESS/(DEFICIT) TRANSFER TO ACCUMULATED FUNDS	<u>\$ 1,023,960</u>	<u>\$ 935,643</u>

The accompanying notes form part of the financial statements.

Children's Leukaemia & Cancer Research Foundation (Inc.)

Balance sheet - 30/06/14

	Note	2013/2014	2012/2013
ACCUMULATED FUNDS			
Balance as at 01/07/2013	\$	7,222,300	6,286,658
Excess/(Deficit) from Operating Statement	\$	1,023,960	935,642
TOTAL ACCUMULATED FUNDS	\$	8,246,259	7,222,300
These Funds are represented by:			
CURRENT ASSETS:			
Cash on Hand	\$	100	100
Cash At Bank	\$	130,911	216,366
Gaming Commission	\$	60,093	58,367
Term Deposits	\$	6,050,754	6,034,367
Total Cash Available	\$	6,241,858	6,309,200
Trade Debtors	\$	76	4,550
Shares - At Cost	\$	17,166	17,166
Share Options - At Cost	\$	1	1
Provision for Diminution in Value	\$	(15,566)	(13,966)
Total Current Assets	\$	6,243,535	6,316,951
NON-CURRENT ASSETS:			
Property - Land & Buildings			
100 Hay St Subiaco At Cost	2 \$	886,630	886,630
Capital Improvements - Subiaco	\$	121,626	121,626
Computer Equipment At Cost	\$	7,183	7,183
Property - Vacant Land			
26 Parnell Pde Bassendean	2 \$	572,928	-
28 Parnell Pde Bassendean	2 \$	553,588	-
Total Non-Current Assets	\$	2,141,956	1,015,439
TOTAL ASSETS	\$	8,385,490	7,332,390
CURRENT LIABILITIES:			
Trade Creditors	\$	(2,026)	(2,942)
Accrued/Sundry Creditors	\$	(115,633)	(76,945)
Leave Liabilities	\$	(65,274)	(61,059)
Provision for AL/LSL on-costs	\$	(6,800)	(6,800)
Total Years Tax Liabilities	\$	50,500	37,655
TOTAL LIABILITIES	\$	(139,232)	(110,091)
TOTAL ASSETS/(LIABILITIES)	\$	8,246,259	7,222,300

Children's Leukaemia & Cancer Research Foundation (Inc.)

NOTE 1- Statement of Significant Accounting Policies

The significant accounting policies which have been adopted in the preparation of this financial report are:

Basis Of Preparation

The Financial Report is a special purpose financial report, which has been prepared to meet the requirements of the Management Committee to provide information to the Children's Leukaemia & Cancer Research Foundation (Inc). The Foundation is not a reporting entity and is not obliged to adhere to the mandatory reporting requirements of the Australian Accounting Standards. Notwithstanding the special reporting status of the foundation, the Management Committee have, unless otherwise stated followed generally accepted accounting principles in accordance with Australian Accounting Standards. The accounts have been prepared on the basis of historical costs and do not take into account the changing value or fair value of non-current assets. The Accounting policies are consistent with those prepared in 2012.

Taxation and GST

Children's Leukaemia & Cancer Research Foundation {Inc} is an income tax exempt body.

The Net amount of Goods and Services Tax and GST recoverable from or payable to the Australian Taxation Office is included as a current asset or liability in the Balance Sheet.

Revenue, Expenses and Assets are recognised net of GST.

Employee Entitlements

The amounts expected to be paid to employees for their pro-rata entitlement to long service leave and annual leave are accrued annually at current pay rates.

NOTE 2 - Valuation of Non-Current Assets - Property

Hay Street, Subiaco was purchased on 02/09/2010 and is valued at cost.

26 and 28 Parnell Parade, Bassendean, were transferred to the Foundation on 17/09/2013 by a deceased estate. They are valued at Committee of Management valuation based upon a real estate agents Appraisal and Report dated 18/09/2012 and a second real estate agents drive-by valuation dated 08/11/2013.

Donations \$100 & Above 2013/2014

Many generous people and organisations gave to the Foundation during July 2013 - June 2014. We have tried to make the following list as accurate as possible but please forgive us if we have omitted details of your gift. Space does not permit us to list the numerous other donations given

Abraham, Greg	Brockway, Joyce	CWA Crafters	Glencoe Primary School	John Septimus Roe
Ahern, Paul	Brooker, Adam	CWA in Tasmania	Global Impact - Alcoa	Anglican Community School
Air Dynamics	Broom, Kevin & Bev	Bruny Island CWA	Goode, Elizabeth	Johnson, Felicity
Alexander, John	Brown, Karen	CWA of WA (Inc)	Gordon, Nicole	Jones, Barbara
Allanson, Brian	Bruns, WP (Peter)	Bayswater Branch	Goss, Elizabeth	Jordaan, Linda
Allardice, CA & MK	Budget Rent A Car	Daniels, Jan	Gourmet Fresh Farms	Jordan, Marion
Amadio, Philip	Burdge, Phillip	Davidson, Maureen	Graham, Rory & Christine	Jouzi, Maryam
Ambrose, Russell	Burgess Rawson (WA) P/L	Davies, Drew	Greenham, Tim & Sue	JP's Trim Shop
AMP Services Ltd	Busselton Old Time Dance Inc	Davies, Lesley	Grieve, Brendon	Jumplings
Angi, G & PA	Busy Fingers Sewing Club	Day, Steve	Grill'd Subiaco	Jupp Allan & Cheryl
APRA Sydney Social Club	Byk, Lanie	DBM Contractors Pty Ltd	Groen, Stephen & Therese	Kane Community Foundation
Ashcroft, Margaret	Cabaret Gaming Pty Ltd	Deane, Jill	Guildford Grammar School	Karosas, Aurimas
Austvending Pty Ltd (SA)	Cahill Albert - Estate of	Deane, Robert	Guilfoyle, Shona	Karratha Bikers Assoc
Aylett, Daniel	Camelia Court Craft Group	Dempers & Seymour Pty Ltd	Haar, Paul	Lower 26th Chapter
Baker Family	Campbell Primary School	Denton, M	Hampton Park Girl Guides	Karratha Earthmoving
Baldivis Primary School	Caporn, Maryanne	Dept of Agriculture	Hampton Park Primary School	Karratha First National
Bamforth, Shannan	Carlisle South Post Office	Dickson, Stuart & Jennifer	Harvey Primary School	Kellogg Joint Venture
Barber, Jessica	Carruthers, Edna	Dilworth Nerida M, Dr	Harvey Senior High School	Kensell, Terry
Barnett, John Mr & Mrs	Carruthers, Wendy	Dorsogna Limted	Hawkins, A	Kerman, Michele
Barrett-Lennard, BR	Caruso, Joseph	Down Frank - Estate of	Henny Robert - Estate of	Kessissoglou, Nicholas
Bathgate, RM & AJ	Catherine Davey Dance Company	Du Preez, George	Hensman Street Kindy	Kirkwood, Kerrin
Baynton West Primary School	Causier, David & Susan	Ducey, Gerry & Beryl	Heritage Lodge No 369 WAC	Kitchen, John & Mary
Bayswater Senior Citizens Assoc	Challis Primary School & Challis ECEC	Duong, Giao Quynh	Heskeith, John & Barbara	Knight, Eric
Beaufort Street 24 Hr Chemist	Chan, Kwan	East Hamersley Primary School	Hick, GB & NE	Kokoda Trek Team - 2014
Beckenham Primary School	Chicken Treat	Eaton Community College	Higgs, W	Kulkarni, Poonam
Bee, Valerie	Australind	Ellenbrook Secondary College	Hislop, Brett	Lacey, P & E
Beechboro Newsagency & Lotteries	Christ Church Grammar	Ellis, Barry & Sue	Hoban, Rosanne	Ladbrook, Jacqueline
Bender, Raymond & Elsie	Christ Church Grammar Romsey House	Entertainment Publications	Hogbin WJ	Ladyman, Basil & Barb
Bennett, Eve	Clarke, Andy	Eresto Pty Ltd	Home Timber & Hardware	Landsdale Forum News
Bentel, Dr Gary & Erica	Clarke Family Trust	Fairchild Audrey	Houghton Wines	Lane John, JP
Beruldsen Margaret - Estate of	CBA - Community Grant	Falconer Family	Howarth Family	Lane, Sandra
Bew, Eric	Como Secondary Collage	Ferguson, Phyllis	Huggins, Helen	Langer Family
BHP Billiton Matched Giving Program	Constantine, Geoff	Findlay Lillias - Estate of	Hughan, John	Lawler, Michael
Bhrara, Tanuja	Cook, Graham	Fisher, Jodie	Hughes, Ian	Lawrence Business Management
Bibra Lake IGS Xpress	Coolup Campdraft Club Inc	Fitzgerald, John	Hume Building Society Ltd	Leaker, Mark & Carmel
Birch, Garry	Cornerstone Lodge No 368	Floreat Ladies 9 Hole Golf Club	Hunt, Greg & Nia	Learmonth Aviation Refueling
Birch, John	Country Womens Assoc	Florusse, C & C	Hutchings, Les & Alice	Lee John Henry - Estate of
Bissaker, Adam	Grass Patch	Focus Real Estate Pty Ltd	Hutchison, John & Norah	Lee, John & Helen
Blythewood Beef Pty Ltd	Coyle, PH & LJ	Franklins Tavern	Huxtable, Glenn	Leeming Senior High School
Bond, GM & M	Cresswell, Richard	Galleria Toyota	Hyde, Rob & Rosemary	Leighton Investments
Boulton, Brian	Cristal Pigment Australia Ltd	Gan, Andrew	In 2 Dance	Leppard, Todd
Brash, James	Crocker, Mark	George, Phil	Jarvis, Stephen Dr	Lewis, Roderick
Brenner, Matt	Crook, Rosalie	Geraldton Senior College	Jenkins Marjorie - Estate of	Lions Club of Coonamble Inc
Bridges, Darren	Crosby, J	Gibbs, Russell	Jennings, Andrew	Lions Club of Cowaramup
Briffa, Yvonne		Gibson, L & M	Jennings, Paul	Lions Club of Ocean Reef Inc
Briggs, Wendy		Gibson, Luke		Lions Club of Serpentine-Jarrahdale Inc
Brightwater House Social Club		Gilbert Family		

Lissiman, Terry & Cindy	Muir, Darryl	Pintabona Charles & Sharon	Slee, Richard & Amanda	Van Duyn, J & TD
Liveringa Livestock Company	Muir, Jon	Poker for Charity Assoc Inc	Smith, Janet	Vanguard Solutions Pty Ltd
Lockyer Robert - Estate of	Nail Plus +	Pollard, Steven	Sound Tax & Accounting	Vassallo, Veronica
Macri, Daniel	National Insurance Brokers Assoc of WA	Precision Collision	Spectra Business Partners	Vibe Baldivis Social Club Inc
Maddern, D	Nedlands Scrabble Club	Preece, Christine	Spencer, Glen	Vicary Gail - Estate of
Mall Managers WA	Needham, Ken & Carroll Gwen	Presence On Preston	St Joseph's School	Vieira, John
Malvern Springs Primary School	Neillings, Robert & Anne	Prider, Carlee	Stan Perron Charitable Foundation Ltd	Vinar Family
Mandurah Over 55's Canoe Club Inc	Netlink Group	Quinn, Jayne	Stanley, Fiona Prof, AC	Vinci, Paul
Mapson, B & J	Nexus Risk Services	Ray White Karratha	Starkey, Geoffrey	WA Primary School Football Championships
Marche Paul - Estate of	Ng, MS & LT	RCWP Trust	State Revenue Office Victoria	Walker, Richard
Marella Nominees P/L	North Woodvale Primary School	Redcliffe Primary School	Statewide Bearings	Walsh Glass
Mastai, Robert & Anna	Northwest Auto Glass	Reed, James	Steinpreis Paganin Charitable Foundation	Ward, Dan
MCB Investments Pty Ltd	Norton, Daniel	Regan, Vincent	Stevenson, D	Warner, Amy
McClymont, Frank	Novus Auto Glass	Repeat Offender	Stewart, M & L	Waterlily Beauty & Makeup Studio
McCorkill, Dr Ron & Michelle	Nursery Australia Pty Ltd	Rhodes, Valma	Sticky Fingers Candy Store	Wellard Group Holdings P/L
McGlynn, Joshua	Ocean Reef Senior High School	Richards, Elizabeth	Summers, Margaret	Wells, Nola
McKendry William - Estate of	Oceania Contracting	Ritz Café	Tan, Wee Hua	West Brothers Sport Leisure
McKenzie, Yvonne	Oenpelli Nominees	Riverside Primary School	Tang, Marcus	Westcourt Consulting Chartered Accountants
McMahon Pauline - Estate of	O'Neil, Ronald	Rockingham Montessori School	Thatcher, Carolyn	Western Australian Youth Strings
Meadow Springs Primary School	Orange Grove Primary School	Rocky Gully Hotel	Think Pink Realty	Westside Golf Club
Meares, Ian & Adrienne	P & A Welding Pty Ltd	Rotary Club of Pinjarra	Thomas, Alan	White, Karla
Melville Scrabble Club	Parkland Villas - Tuesday Afternoon Craft Group	Rotary International Dist 9465	Thompson, Jan	White Lady Funerals
Meneghello Galvanising Industries	Parry, David	Rowell, Rob	Thornlie Bowling Club	Wilkinson, Cheryl
Menzies Family Trust	Patrick, Gordon & Jean	Rowley, Eleanor Dr	Thornton, Alan & Danielle	Wilkinson, Trevor
Methodist Ladies College	Patterson, Mark	Royal Life Saving Society (WA)	Titshall, Susan	Williams, Alison
Michales, Paul & Effie	Paulin, Antony	Rutherford, David	Tomkinson, Neil & Rosemary	Wilson, Barbara
Middleton, Helen	Pearce, Natasha	Sanderson, L & KG	Toohey, John	Wiseberry Heritage Real Estate
Mining People Internatinal Pty Ltd	Pearsall Primary School	Saunders ,Joan	Toolmart Australia Ltd	Wood, Daniel & Holly
Mischin, Hon Michael, MLC	Pember, Bronte	Saville, Peter & Sandra	Toscana (WA) Pty Ltd	Marshall-Wood
Mocevic, Sandra	Perth Racing	Searle, Cherrie	Trezeise, Ron & Barbara	Wood, Simon & Stacey
Moles, Dr Aaron & Cathy	Perth Liverpool Supporters Club	Senior, CG Mr & Mrs	Trist, Cherry	Woodlands Primary School
Morrison, Ken & Margaret	Perth Smart Centre	Shean Pty Ltd	TSRhorizons Consulting	Woodley, Elizabeth
Mount Hawthorn Primary School	Dept. of Human Services	Shephard, Glenice	Tuite, Helen	Woolett Partners
	Peterson, Jocelyn	Sheppard, Gail	Ultra Printing, Promotional Products & Workwear	Woollett, S & R
	Peters-Smith, Adrian	Shire of Capel	United Fundraisers	Wyllie, M & H
	Philp, Betty	Shreeve & Carslake Pty Ltd	Vaiciunas, M	Yakamia Primary School
		Sils-Ohlsen, Edmund	Van Dijk, H & C	
		Sim, Paula		
		Skinner, Samantha		

Gifts or Services in Kind

AEG Ogden
 AAM Group
 Allion Legal
 Asvante Designs
 Australia Post Carlisle South LPO
 Australian Protection Services
 Aus Stereo - Linda Wayman
 Beans & Bunches Flowers
 Beverley Margaret School of Dance
 Busy Fingers Sewing Club

Brenner, Matt
 Digital Imagineers
 Central Tafe
 City of Perth
 Claremont Art Framers & Gallery
 Entertainment Publications
 Everyday Hero
 Grape Expectations Vintners
 Go Fundraise
 Happs Margaret River
 Hello Call Centres
 Houghton Winery
 Kennards - North Perth
 KC Tools

Langer Justin - Patron
 La Mint Events & Catering
 Lord Mayor of Perth, Hon Lisa M Scaffidi
 Mayor of the City of Vincent, Mr John Carey
 Midland Energy
 Minister for Education, Hon Peter Collier, MLC
 MRA
 My Cause
 OutCased
 Pallet Media
 Parker, Rose
 Perth Airport
 Perth Theatre Trust

Pizza Express Hilton
 Premium Beverages
 Quality Printer Cartridges
 Quik Impressions
 Repeat Offender
 Royal Life Saving Society of WA
 Seashells
 Scotch College
 Scott, Sarah
 State Theatre Centre of WA
 Telethon Kids Institute
 Top Shelf Web Design
 Treasure, Simon
 Wood, Graham

Schedule of Members 2013/2014

A

A'Court Susan
 Agostino Melina
 Agribusiness Research & Management
 Ahern Muriel
 Alban Anselma
 Alexander Andrea & Gordon
 Allen Ebony
 Allen Elizabeth
 Allen Family
 Al-Saffar Karim
 Anderson Kimon & Sondra
 Anthony Ted
 Antiskid Pty Ltd
 Anzellino Dom
 Archibald Lesley
 Arnold Geoffrey
 Astone Joe & Ivy
 Aubin Paula

B

Bailey Philip
 Baker David Dr
 Baker Family
 Bakers Phil
 Ballantyne Patricia
 Barbas Family
 Barnett John
 Barrett Margaret
 Barrett-Lennard BR
 Batchelor Roy
 Bate Warren & Mandy
 Bauer Christian
 Bayliss Steve
 Beake Jim
 Bee Valerie
 Beer Campbell
 Bell James
 Bender Elsie
 Bender Raymond
 Bender Sophie
 Bennett Michael & Vicki
 Bennett Peter & Angela
 Bennett Iris
 Bentley Jan
 Bingham Julie
 Blampey Matthew
 Bombardieri Patricia
 Boogaard Annette & Austin Ken
 Boucaut Gary
 Boulton Brian
 Bowater Valma
 Boyd James
 Bradshaw Elizabeth & John
 Brand Beth

Brassington John
 Brennan Anthony
 Bridson Suad
 Brockway Frank
 Brodie-Hall R & C
 Broom Kevin & Bev
 Brown Amber
 Brown Gerry & Thea
 Brown Colin & Glenice
 Bruce Charlotte & Rob
 Bruce Justin
 Bruce Kristy
 Bruce Philip Life Member
 Bruce Family
 Budd Joy
 Bunn Tania & Loren
 Burdge Phillip
 Burgess Donald (Canada)
 Burns Faith
 Butcher Doug

Butler Robyn
 Buttfield Jan
 Byers Dorothy
 Byrne Bridy, Jnr M
 Byrne Grady, Jnr M
 Byrne Lily, Jnr M
 Byrne Murphy, Jnr M
 Byrne Riley, Jnr M
 Byrne Troy, Jnr M

C

Cairns Bruce & Debra
 Calleja John
 Campbell Bruce OAM
 Cantone Joseph
 Carr Daniel & Kasey
 Carvajal Tony
 Cattach David & Jenny
 Cattach Brent
 Cattach Geoff, Life Member
 Cattach Marie
 Cattach Stewart
 Causier David & Susan
 Celisano Carlo
 Chandler Geoff
 Chapman George & Lucy
 Chapman Janine
 Chapman Family
 Charles Foti Business Services
 Chong Bryan – Jnr M
 Christian Bret
 Clark Michael & Jane
 Clark Robert & Sue
 Clark Rowan
 Clarke Wayne
 Cleave A & B

Clifford Alistair
 Cochrane Debi
 Cocking Barbara
 Cole Catherine Dr
 Collings Arlene
 Colwill June
 Condello Ralph
 Connor Judith
 Cooke John
 Coote Annette & Kevin
 Cotter Carolyn & Gary
 Couzens Kathleen
 Covich John
 Crawley Nigel
 Criddle Jack
 Crook Rosalie
 Crooks Rosemary
 Crosby Edith
 Crowle Peter

D

Daljac John
 Daniels Jan
 Davidson Sandra
 Davies Lesley
 Davis Lesley & Tony
 Day Bryce, Jnr M
 Day Karri, Jnr M
 Day Kevin & Sue
 DBM Contractors P/L
 De Chiera PS & DM
 De Gruchy Dorothy
 De Nooyer Len
 De Petra Dawn & Genelle
 Del Corso Nathalie
 Delroy MD Neil
 Detiuk Michael & Georgina
 Detiuk Nicholas & Yvonne
 Devine Kerry & Catherine
 Di Biase Bianca
 Di Candilo Steel City
 Dickson Stuart & Jennifer
 Di Masi L & E
 Dodd E F
 Downe Rod
 Draper Stephen & Karen
 Duane Bec
 Ducey Gerry & Beryl
 Dunham Richard & Kathleen (USA)
 Dunning Vaughan
 Duxbury Helen
 Dwyer Amy
 Dyson C
 Dzal Vicky
E
 Edmunds BK & DM

Edwards Murray
 Elliott Mary
 Elliott Margaret
 Ellis Barry & Sue
 Ellis Steve & Doreen
 Emmett Audrey
 English Skye May (Jnr)
 Escott Brenda

F

Fahrner Helke Dr
 Falconer David, Leanne & Family
 Falconer Moira
 Falconer Peter, Life Member
 Fardon Andrew & Jackie
 Farquhar Sharna
 Fawcett Bob & Jan
 Fawcett KE
 Fels Brian
 Fergusson Helena & Brendan
 Fiorenza Tony
 Fisher Kellie
 Fitzgerald John
 Fitzpatrick Robyn
 Flavel Don
 Flis Family
 Florusse C & C
 Foote June & Allan
 Ford Jette & Peter
 Fowler Jennifer
 Francis Rosslyn
 Fraser Anne & Neil
 Fraser Heather
 Fraser Ciara, Jnr M
 Fraser Michael, Jnr M
 Frawley M & S
 Frossos Family
 Frost Petra
 Froude Winifred

G

Gabelich Debra
 Galati Cono & Trudy
 Galati Vincent & Pamela
 Gangemi Lynette
 Garas Monier
 Garner Family
 Geddes David & Charlotte
 Gee Marie
 Genovese Family
 George Janet
 Germain Terrence
 Germs Leanne
 Gerschow Otto
 Gibson Lisa
 Giglia Lou & Maria
 Gilbert Family

Gilbert Vanessa

Gill Kevin & Cherryl

Gilna Michael & Linda

Ginbey Robert & Marie
 Giorgio Carmela
 Glass Thelma
 Gobbart Rhona
 Gobby Geoffrey
 Godfrey Allan & Fiona
 Godfrey Greg & Linda
 Goetz Marilyn
 Goldsworthy Cathy
 Goullos Philip
 Goyder John & Pam
 Graham Rory & Christine
 Graham Valerie
 Grant Rosemary
 Gray Jill
 Green Bobbie
 Greenham Tim & Sue
 Grosser Kerry
 Grossman Otto
 Gucciardi Tony & Lisa
 Gunellas Yvonne

H

Hagan Merv
 Haig John
 Hall Cassie, Jnr M
 Hall Family
 Hambley Bill & Rita
 Han Edward & Francis
 Hanley Garry
 Hanssen Gerry
 Hargrave Stephen
 Harper Margaret
 Harper Peter, Life Member
 Harris Eileen
 Harris Murray, Helen & Justin
 Hart Linda & Roy
 Harwood Fran
 Hawley Dave
 Hayes Sharyee
 Haynes John
 Heal Eric & Judy
 Heal Valda
 Heenan Elizabeth
 Heil Adrian
 Herlihy Geoffrey
 Hesketh John & Barbara
 Hewett Mitch
 Hicks David & Pam
 Hicks Gillian (UK)
 Hiddlestone Kay
 Hiddlestone Natalie
 Hiddlestone Kay
 Hill A
 Hill Charles & Joan
 Hill Roger
 Hill Stan & Beryl
 Hillaert Francoise
 Hilton Lynette

Hogben Terry
 Holly Grace & Tiny
 Holman Leah
 Holmes Martin
 Horrocks Megan
 Hortle Jan
 Howarth Family
 Howe Suzanne
 Howell Sue
 Huggins Joanne
 Hugo Chris & Amanda
 Hutchings/English Brad & Cassandra
 Hutchings Les & Alice
 Hyde Rob & Rosemary
 HWE Maintenance Services Pty Ltd

I

Ieraci Cosi & Casey
 Ieraci Renae
 Ieraci Stefan
 Ieraci Tony & Lorna
 Italiano Robert & Minnie
 Italiano Harley, Jnr M
 Italiano Tyson, Jnr M
 Italiano Zak, Jnr M
 Ivory Valma

J

Jackson Tanya & Trevor
 Jackson Vicki & Neil
 James Errol
 Janiec Edward
 Jarvis Stephen Dr
 Jayawardena Shamal
 Jenkins Graeme
 Jennings Brian
 Jennings Ian & Val
 Johnson Felicity
 Johnson Maureen Kay
 Jones Clive
 Jones Susan
 Jones WB
 Joyner Simon
 Jupp Cheryl & Allan
 Jury John

K

Keane Brian
 Kearns Gary & Wendy
 Keefe Faye & Phil
 Keighran Dean
 Kelly J
 Kelly Linda
 Kelly-Cook Danielle
 Kenda Lloyd & Detiuk Tanya and Family (Hong Kong)
 Kenda Renato & Annette
 Kerr Margaret
 Kiernan Barbara

Kijak Eva Dr
King Barbara
King Felicity
Kinnear Brett & Christine
Kirkwood Kerrin
Kitchen John & Mary
Knight Jeffrey Dr
Koelen M & J
Konigsberg Hilary
Kounis Kaye
Krikke Peter
Kumagai Hiromi

L

Lamb Phil
Lane, John (JP)
Langdon Mark
Langer Joy-Anne
Langer Ali-Rose, Jnr M
Langer Grace, Jnr M
Langer Jessica, Jnr M
Langer Justin, Patron
Langer Sue
Langer Sophie, Jnr M
Larke Graham & Althea
Lata Roshni
Lawrence Susan & Shaun
Laycock Ruth
Lazzarich Family
Le Page Michael & Maria
Lee John & Helen
Leeffang Cathriena
Liddelow Glen Dr & Alessandra
Lodge Robert & Gail
Lombardi Shirley
Love Murray
Loveridge Camilla & Gavin
Lovett Craig
Lowry Georgia, Jnr M
Lush Katelyn
Lychlander Sheila
Lydon Larry & Isabell
Lynch Emily
Lynch Andrew
Lynch Bruce & Glenda

M

MacDonald Kevin & Eileen
MacFarlane Kerry
Mackey Rob & Grace
MacLean Christine
MacLeod Jessie
MacLeod Patricia
MacPhail Duncan & Julie
Mainwaring Kiren & Kelli
Mancuso Maruzza
Manning Peter
Manuel Don & Pat
Marchant Family
Marinich Jeanette

Marra Rolando
Marron Bret & Jane
Marron Chelsea
Marsell William Dr
Marshall Marion
Martin Evelyn
Martin Robyn
Martin Sharon
Masarei John Dr & Marylee
Massara Family
Mathews Kerry
Matthews Daniel
Mathews Neville
Mathews Wendy
Mattia Renata
Maughan Chris & Olive
McAullay Darren
McCallum Family
McClymont Frank
McCorkill Ron Dr & Michelle
McCormick Dorothy
McCormick Steven & June
McCusker Malcolm, AO, CVO, QC
McDonald Ian & Penny
McEwen Amanda & Grant
McGinty Hazel
McGrath Warren
McKay Lex
McKenzies Auctioneers, Valuers & Exhibitions
McNeill Pamela
Meenworst ME
Merillo Joseph & Elsma
Mignacca Sharon
Mignacca Emily, Jnr M
Mignacca Michael, Jnr M
Millband Margaret
Miller Rusty & Barbara
Miller Ross
Mills Alistair Dr
Mills Jenny
Mills Nancy
Milner Warren
Milton Nui & John Dr
Mischin Michael MLC
Mitchell Colin
Mitchell Family
Mitchell Justine
Mitchell Margaret
Moir Sue
Morrissey Jenny
Moss Trisha
Muir Darryl
Muir Jon
Murray Wendy
Myers John
Nabbs David & Pam

N

Nabbs Declan, Jnr M
Nabbs Holly, Jnr M
Nabbs Sarah, Jnr M
Nabbs Sophie, Jnr M
Napier Kath
Navarro Martin
Neillings Kaye
Newton Beth
Nolan Brendan
Norton Daniel
Noske Kim & Gillian
Nottle Pat
Nowland David & Susanne
Nunn Malcolm & Leanne
Nyenhuis Brigitte & Harry

O

Oldham Neil & Shirley
Oldham Tracey
Oliver Jean
Oliveri Antonio & Santina
O'Neill Lawrence
O'Neill Shane
Ong Jung Shen
Ong Siew Geok

P

Palmer Patricia
Panizza Rachel
Parker Judith AM DSJ
Parker Kane
Parker Michael & Cathrin
Parkin Peggy
Parry David
Paulin Anthony
Payne A
Peaker Shirley
Pech Judith
Perkins Roy
Philp Ray
Pickett EF
Piggott Sam
Pike Vanna & Les
Pintabona Charles & Sharon
Pontre Securities Pty Ltd
Preece Christine
Price Esther
Purcell Michael

Q

Quinn Judy
Quiñones Susanne
R
Ratcliffe Alan & Sue
Ratcliffe Sean
Rate Yvonne
Rex Caroline
Reynolds Abby
Reynolds Dwayne - Drillshop
P/L
Richards Celia

Richards Elizabeth
 Ridge Debra & Mark
 Rigali Daniel, Damien & Elia
 (Gourmet Fresh Farms)
 Rijkuris Teodors & Pixie
 Riley Mary & Geoff
 Roberts Carolyn
 Robertson Ian & Cecily
 Robins Mark, Jnr M
 Robins Sarah
 Robins Trudie Joy
 Robinson Graeme & Priscilla
 Rodoreda Greg & Michelle
 Roebuck Simon
 Roffey Scott
 Rolliston Jack, Jnr M
 Rolliston Linda
 Rolliston Peter
 Rolliston Samantha, Jnr M
 Rolliston Tonya, Jnr M
 Rose David
 Rose Steven & Helen
 Rossen Real Estate
 Rotary Club of Bunbury
 Rotary Club of Harvey
 Rotary Club of South Bunbury
 Rowan Zenobia
 Rudd Kim
 Russell Bill
 Rutherford David
 Ryan Jarred & Amanda
 Ryan Nicholas

S

Salamone Rebecca
 Sanders Luke
 Sarti Rhonda
 Savage Dean & Paulette
 Schmid Charlie
 Schneider Darren & Cheree
 Schulze Dean
 Scolaro Patricia
 Scott Graham & Linda
 Segal Leah
 Seidelin Erik & Helen
 Senior Sue
 Sequeira Andre & Neicha
 Shackleton Aaron
 Silbert Lindsay & Suzanne
 Silsbury Robin
 Sim Paula
 Simons Eileen
 Sinclair Family
 Skinner James & Patricia
 Skinner Joy
 Skinner Samantha

Sladden Mark & Julie

Slatter Brian

Small Craig & Melanie

Smith Catherine
 Smith Jim
 Smith Masie
 Smith Philip
 Somes Jane
 Spagnolo Family
 Spalding Ivan
 Spalding Maurie
 Sparks Amanda
 Spence Charles
 Spencer J & E
 Stanley Brian
 Stanley Fiona Prof, AC
 Starkey Lorraine & Stephen
 Steel Christine & Peter
 Stevens Glen & Beverley
 Stewart Annette & Tahlia
 Stokes Marie
 Stokman Gerda
 Stone Stephen
 Stopp Bryn & Nicole
 Stopp Shane & Hayley
 Stopp Todd & Orlagh
 Stopp Valerie
 Storrs Julia
 Stratton Veronica
 Street John
 Stuchbury Laura & Mark
 Sugg LW & AJ
 Sullivan Brian & Shelley
 Susomrith Pattanee
 Sutton Peter & Glenda

T

Tassone Joseph
 Taylor Alan & Michelle
 Taylor JR Dr & MM Mrs
 Teague Cheryl
 Teague Trent, Jnr M
 Tedla Shewanesh
 Teraci Paul
 Terms Alexandra
 Terry Philippa
 Thomas Family
 Thomas Peter
 Thomason Tony
 Thompson John R & Shelley
 Thompson Melvyn & Carol
 Thompson Ted
 Thornton Janine
 Trewren Edith
 Troncone Susan & Fred
 Tsapazi Luke
 Turner Glen
 Turner Jim
 Turner Keven Dr & Fay

U

Udinga Jan & Alex

Uros Deanne & Timm

V

Vale Jo
 Valom Hendrik
 Van Burgel Gary, OAM, JP
 Van De Beek Patricia & Paul
 Van Der Lecq P & A
 Van Dijk B & C
 Van Duyn J & TD
 Van Mansum Jeanette & Paul
 Verbrugge Vanessa & Vanessa
 Villa Gillian
 Vinar Family
 Vittino Ric & Jackie
 Vogel Reto
 Vogels Linda

W

Wadsworth Jennifer
 Walker Richard G
 Wallace M-J
 Walters Barry Dr
 Walton Amy & Drew
 Walton Judi
 Wannberg Family
 Wards Joseph
 Warn Rose
 Warner Amy
 Warwick Lorraine
 Warwicker Shirley
 Webb Brian & Maxena
 Webster Claudia
 Webster Steven
 Weldt Godfrey
 Weldt Theckla
 Weldt Therese
 Werner Patricia
 White Ron & Cheryl
 Wickham Gail & Graeme
 Wieclaw Josef
 Wigger-Smith Courtney
 Wilborn Bernie
 Wilborn Ganesh, Jnr M
 Williams David & Kirsten
 Williams Rosemary
 Williamson Kim & Jenny
 Williamson Jocelyn & Robert
 Wilson Lorna
 Wilson Stephen Dr
 Wolfe Jeanette
 Wong Joe & Dr Cheryl
 Wood Brendan & Margaret
 Wood David
 Wood Simon & Stacey

Y

Young Duncan & Annie

Z

Zuchner-Mogall Gisela

Cover

- *Dance for a Cure 2014*
- *Keep the Flame Alive Business Launch*
- *Guinness World Record for the “Longest Awareness Ribbon”*